Biovail Corp. has made changes to its business infrastructure, reorganizing itself into three distinct business units: Biovail Drug Delivery (BDD), which comprises Biovail’s drug-delivery technologies, its drug-development capabilities and its strategic partnerships; Biovail Pharmaceuticals U.S. (BPUS), which focuses on the promotion of products to specialists in niche therapeutic markets; and Biovail Pharmaceuticals Canada (BPC), which promotes products to both to specialist and primary-care physicians in Canada.

“The constantly changing dynamics of the global pharmaceutical marketplace have made it necessary for Biovail to further refine the organizational infrastructure that supports its business,” said Dr. Douglas Squires, chief executive officer of Biovail. “The changes that we’ve announced will further enable Biovail’s Business Units to facilitate our mission and key core competency—to apply advanced drug-delivery technologies to improve the clinical effectiveness of medicines.”

The company has also made changes to its executive management team. Greg Gubitz, formerly chief operating officer at MDS Capital Corp., has been named senior vice president, Crystaal Pharmaceuticals. Mr. Gubitz will assume a leadership role in the proposed spin-off.

Dr. Gregory Szpunar, senior vice president, R&D and chief scientific officer, will leave Biovail to pursue a senior position with a large pharmaceutical company. The company expects to name his successor shortly.